Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Nektar Therapeutics has created two new units as part of plans to drive the company's PEGylation and pulmonary research initiatives.
Subscribe to our email newsletter
The new structure is claimed to align Nektar’s research activities with its strategic business objectives, and allow for better decision-making and portfolio prioritization. The company has also appointed two vice presidents to head its new research units.
Tim Riley, is being promoted to serve as vice president of the PEGylation research unit reporting to Hoyoung Huh, COO and Head of PEGylation business unit. Mr Riley will head research activities for all product candidates using Nektar’s proprietary PEGylation technology platform, including Nektar PEG small molecule products in the areas of oncology and CNS/pain.
John Sisco, is being promoted to serve as vice president of the Pulmonary research unit reporting to Nevan Elam, senior vice president and head of Pulmonary business unit. In his new role, Sisco will lead the company’s research activities for all product candidates that leverage Nektar’s proprietary Pulmonary technology platform, including the company’s inhaled antibiotic programs.